Head and neck squamous cell carcinoma Trials in London, United Kingdom
Conditions / Head and neck squamous cell carcinoma / London, United Kingdom
Head and neck squamous cell carcinoma has been the subject of sustained clinical investigation across multiple research sites.
26 total trials for this combination
Showing top 10 of 26 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04199104 | A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010) | COMPLETED | PHASE3 |
| NCT06525220 | A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1) | RECRUITING | — |
| NCT06496178 | A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients | RECRUITING | PHASE3 |
| NCT04032704 | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | TERMINATED | PHASE2 |
| NCT06465069 | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors | RECRUITING | PHASE1 |
| NCT03526835 | A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors | RECRUITING | PHASE1/PHASE2 |
| NCT06525220 | A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1) | RECRUITING | — |
| NCT06525220 | A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1) | RECRUITING | — |
| NCT04254107 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | TERMINATED | PHASE1 |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | TERMINATED | PHASE1/PHASE2 |